These data support the ongoing phase III HERTHENA-Lung02 (NCT05338970) trial evaluating HER3-Dxd versus standard-of-care chemotherapy in EGFR-mutated progressed NSCLC [130]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.